Finance & investment, Research & education

From clinic to claim: The health professional’s guide to the R&D Tax Incentive

Beth Micklethwaite

Published: 23 Oct 2025

read time 4 min

Key learnings

The R&D Tax Incentive (R&DTI) can provide health startups and SMEs with a cash refund of up to 43.5% on eligible research and development spending.
Only companies are eligible – not sole traders, partnerships or most trusts – so structuring correctly from the outset is critical.
Eligible activities must involve solving a genuine technical uncertainty through systematic experimentation, not just applying existing knowledge.
Clinical trials for unapproved therapeutic goods are automatically considered Core R&D Activities, streamlining claims for MedTech and biotech ventures.
Meticulous, real-time documentation is essential to survive audits and avoid clawbacks.

In operating theatres, physiotherapy clinics, and MedTech labs across Australia, health professionals are reimagining patient care. But there’s one thing that a new biodegradable heart stent and a new VR-assisted rehab protocol have in common: both innovations take time, talent and serious funding.

The Australian Government’s R&D Tax Incentive (R&DTI) is one of the most powerful tools for turning those ideas into reality. For companies with less than $20 million in aggregated annual turnover, it offers a refundable tax offset equal to the company tax rate plus an 18.5 percentage point premium – 43.5% for most small companies on a 25% rate.

For pre-revenue startups, that’s non-dilutive capital in the bank, without giving up equity to investors.

In a global health innovation race where Europe and Asia are aggressively courting R&D dollars, the R&DTI is designed to keep Australian discoveries both local and commercially viable.

The catch? You need to understand the rules, structure your business correctly and treat the program as a strategic funding source, not an end-of-year bonus.

What counts as R&D in healthcare?

Great question. Not all innovation qualifies.

The program defines two categories:

Core R&D activities: Experimental work designed to generate new knowledge, where the outcome can’t be known in advance based on existing public information. It must follow a scientific method: form a hypothesis, test it, observe results and draw conclusions.
Supporting R&D activities: Work directly related to Core R&D, such as literature reviews, creating a prototype or calibrating specialist equipment. If these activities involve producing goods or services, you must prove their dominant purpose is supporting the core experimentation.

Examples in healthcare:

Eligible:
- Developing a novel neurostimulation device for ADHD and running trials to see if it works as hypothesised.
- Creating a needle-free vaccine delivery system and testing whether it performs better than current methods.
Not eligible:
- Using an existing TGA-approved device exactly as intended to improve patient outcomes.
- Adapting off-the-shelf software for patient bookings without solving a technical uncertainty.

One standout feature for the sector: Phase 0 to III clinical trials for unapproved therapeutic goods are automatically deemed Core R&D Activities under the Industry Research and Development (Clinical Trials) Determination. You still need to register your activities and meet other program rules, but you won’t have to prove their experimental nature.

The money Side: Turning experiments into capital

For startups and SMEs (<$20 million turnover)

The refundable offset is the real game-changer. Spend $100,000 on eligible R&D and you could see $43,500 back as a cash refund, even if you’re running at a loss. You can use that money in several different ways to benefit your business.

For larger organisations (≥$20 million turnover)

The incentive becomes a non-refundable tax offset, reducing your company’s tax bill now or in future years. Rates are tiered based on “R&D intensity” (the percentage of total expenditure that’s R&D-related) with higher rates for companies deeply invested in innovation.

Minimum spend: $20,000 annually, unless the R&D is conducted through a Registered Research Service Provider or via a monetary contribution to a Cooperative Research Centre. The maximum premium applies to the first $150 million of eligible expenditure each year; above this, the offset reverts to the company tax rate with no premium.

Get your structure right from day one

This is where many health innovators fall at the first hurdle. The R&DTI is only available to companies incorporated under Australian law (or certain foreign companies with an Australian presence). Sole traders, partnerships, individuals, and most trusts cannot claim (except for public trading trusts with a corporate trustee).

And timing matters. If you run experiments in a trust and only later form a company, those early expenses are gone forever in R&D terms. Incorporating before you begin ensures costs are linked to an eligible entity and that intellectual property is properly owned and protected.

Disciplined documentation

A defensible R&D claim lives or dies on its records. Regulators want proof of a systematic experimental process, not a retrofitted summary months later.

Key records to keep in real time:

Planning documents: Literature reviews, patent searches, and project plans showing the technical gap you aimed to close.
Experimental data: Lab notes, testing logs, prototypes, photos, videos and analysis of results for each iteration.
Financial evidence: Timesheets linking staff hours to R&D tasks, invoices for materials and payment records.
Final outputs: Internal reports, patent filings or conference presentations demonstrating new knowledge generated.

Registration with AusIndustry must be completed within 10 months of your income year-end (extensions only by application through the customer portal). Miss it, and the claim is gone.

Avoid the “7 deadly sins” of R&D claims

Wrong business structure: Conducting R&D in an ineligible entity.
Assumption-based claims: Thinking innovation equals eligibility without proving technical uncertainty.
Poor documentation: Failing to keep contemporaneous records.
Whole-project claims: Including commercial or production work instead of isolating eligible activities.
Software pitfalls: Claiming standard app development without experimental elements or for internal administration.
Ineligible costs: Marketing, compliance filings, or unrelated overheads.
Missed deadlines: Blowing the 10-month registration cut-off.

Turning innovation into an asset

The R&DTI isn’t a freebie – it’s a reward for structured, well-documented problem-solving. When embedded into your financial strategy from day one, it can reduce your risk, make investor conversations easier and extend your cash runway.

Key takeaways for Australian health professionals at the edge of science and patient care are to:

Plan early: Align your project with eligibility criteria before you spend a dollar.
Structure smart: Incorporate as a company before starting work.
Document religiously: Treat record-keeping as part of your scientific process, not an afterthought.

By doing so, you turn your big idea into both a medical breakthrough and a bankable business asset.

References